Figure 5.

DFOM alleviated LPS/D-GalN–induced ALF by inhibiting ferroptosis. (A) The survival rate of WT mice treated with vehicle or DFOM (100 mg/kg) 1 hour before LPS/D-GalN co-injection (n = 5). (B) Serum levels of ALT and AST from WT mice with vehicle or DFOM before LPS/D-GalN co-injection (n = 5). (C) Serum of Fe²⁺ levels of WT mice with vehicle or DFOM before LPS/D-GalN co-injection (n = 5). (D) Representative pictures for H&E and TUNEL staining of WT mice with vehicle or DFOM before LPS/D-GalN co-injection (n = 5). (E and F) GSH and MDA assay of liver homogenates from WT mice with vehicle or DFOM before LPS/D-GalN treatment (n = 5). (G and H) Western blot analyses of CHAC1, POR, TFR, and Ptgs2 from WT mice with vehicle or DFOM before LPS/D-GalN treatment and ratios of each protein to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (n = 6). (I and J) Western blot analyses of DHODH, FSP1, GPX4, and XCT from WT mice with vehicle or DFOM before LPS/D-GalN treatment and ratios of each protein to GAPDH (n = 6). All data were obtained from WT mice. Scale bars: 100 μm. Data are presented as means ± SEM. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001. D-GalN, D-galactosamine.